Mega Lifesciences PCL (BKK:MEGA) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mega Lifesciences PCL's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

Mega Lifesciences PCL's long-term debt to total assets ratio increased from Dec. 2023 (0.01) to Dec. 2024 (0.01). It may suggest that Mega Lifesciences PCL is progressively becoming more dependent on debt to grow their business.

Mega Lifesciences PCL LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mega Lifesciences PCL's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL LT-Debt-to-Total-Asset Chart

Mega Lifesciences PCL Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Mega Lifesciences PCL Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Mega Lifesciences PCL LT-Debt-to-Total-Asset Calculation

Mega Lifesciences PCL's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	139.826	/	14210.134
	=	0.01

Mega Lifesciences PCL's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	139.826	/	14210.134
	=	0.01

Mega Lifesciences PCL (BKK:MEGA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mega Lifesciences PCL LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Lifesciences PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MEGA-R:Thailand

Address

Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea, Bangna, Bangkok, THA, 10260

Website

https://www.megawecare.com

Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL Headlines

No Headlines